Details checkedClinical trial listing onlyHistorical/discontinuedCheckedregistry

Anakinra Studies in Autoimmune Inner Ear Disease and Steroid-Resistant SSNHL

Also known as: Anakinra, Kineret, Autoimmune Inner Ear Disease, Steroid-resistant sudden sensorineural hearing loss, NCT01267994, NCT02414152

Investigator-led study

Primary source

Sponsor / Institution

Investigator-led study

Program Type

Therapeutic

Modality

Biologic

Stage

Phase 1/2

Status

Completed

Target Gene

—

Route / Mode

Subcutaneous injection

Confidence

84%

Status Confidence

Status needs checking

Evidence Strength

Needs more support

Last Reviewed

2026-06-10

Geography

United States

Population

adult, sudden, autoimmune-inner-ear-disease

Trial IDs

Mechanism

Investigator-led Phase 1/2 studies of subcutaneous anakinra/Kineret in corticosteroid-resistant autoimmune inner ear disease and sudden sensorineural hearing loss.

Indications

Hearing Loss Sensorineural Hearing Loss Sudden Sensorineural Hearing Loss

Notes

Verified as two investigator-led anakinra hearing-loss studies. NCT01267994 completed in autoimmune inner ear disease; NCT02414152 was terminated in steroid-resistant sudden sensorineural hearing loss. HearScape should treat this as a historical repurposed-biologic study cluster rather than an active industry program.

Evidence & Sources

2 structured sources

clinicaltrials

Supports: canonicalName, aliases, company, allCompanies, isIndustrySponsored, programType, modality, mechanism...

IDs: NCT01267994

Open

clinicaltrials

Supports: canonicalName, aliases, company, allCompanies, isIndustrySponsored, programType, modality, mechanism...

IDs: NCT02414152

Open

Key Events

2011-06-01